Evidence map›Paper›PMID 34059940›Full record

ArticleApplied microbiology and biotechnology2021

A screened PirB antagonist peptide antagonizes Aβ

Zheng Zhang, Zijian Wang, Zhipeng Ling, Yu Li, Junping Pan, Qin Gao, Jichun Zhang, Li Yan, Zhidong Zhang, Junliang Li and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Immune receptors and aging brain.Bioscience reports · 2024
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Zheng Zhang *Department of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Zijian Wang *Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, China.
Zhipeng LingDepartment of Microbial and Biochemical Pharmacy, College of Pharmacy, Jinan University, Guangzhou, China.
Yu LiDepartment of Pharmacology, School of Medicine, Jinan University, Guangzhou, China.
Junping PanInstitute of Geriatric Immunology, School of Medicine, Jinan University, Guangzhou, China.
Qin GaoDepartment of Pharmacology, School of Medicine, Jinan University, Guangzhou, China.
Jichun ZhangDepartment of Physiology, School of medicine, Jinan University, Guangzhou, China.
Li YanFormula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Zhidong ZhangDepartment of Pharmacy, The First Affiliated Hospital, Jinan University, Guangzhou, China. tzzd0608@jnu.edu.cn.
Junliang LiDepartment of Neurosurgery, Guangzhou Women and Children's Medical Center, Guangzhou, China. junliangli@aliyun.com.
Fei XiaoDepartment of Pharmacology, School of Medicine, Jinan University, Guangzhou, China. xiaofeicn@163.com.ORCID http://orcid.org/0000-0003-3370-4234
Jinan University · CNFirst Affiliated Hospital of Jinan University · CNGuangzhou Women and Children Medical Center · CN

Funding

Fundamental Research Funds for the Central Universities 11620425 to JZNational Natural Science Foundation of China 81202519National Natural Science Foundation of China 81903617Natural Science Foundation of Guangdong Province 2019A1515010936Science and Technology Program of Guangzhou Province 202002030079
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a type of progressive neurodegenerative disease, and amyloid β-protein 42 (Aβ

Indexed as

Amyloid beta-PeptidesNeurodegenerative DiseasesNeuronal OutgrowthCells, CulturedHumansMembrane GlycoproteinsPeptide FragmentsReceptors, ImmunologicAmyloid beta-PeptidesMembrane GlycoproteinsPeptide FragmentsPILRB protein, humanReceptors, ImmunologicAlzheimer’s diseaseAβ42Nerve regenerationPaired immunoglobulin-like receptor BPhage display technology

Identifiers

PMID34059940
OpenAlexW3164181552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.